Compare BRSP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | CAPR |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.9M | 584.9M |
| IPO Year | 2017 | 2011 |
| Metric | BRSP | CAPR |
|---|---|---|
| Price | $3.70 | $6.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $5.97 | ★ $27.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 16.89% | N/A |
| EPS Growth | ★ 75.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,587,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.19 | $1.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.70 | $2.96 |
| 52 Week High | $6.17 | $40.37 |
| Indicator | BRSP | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 29.26 | 39.26 |
| Support Level | N/A | $6.01 |
| Resistance Level | $3.94 | $10.12 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 10.34 | 9.03 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.